Comparative study of four fluorinated quinolones in susceptibility factors on microorganisms by Patel, Ketul R
COMPARATIVE STUDY OF FOUR FLUORINATED QUINOLONES IN 
SUSCEPTIBILITY FACTORS ON MICROORGANISMS. 
by 
KETUL R. PATEL 
Submitted to the 
Office of Honors Programs and Academic Scholarships 
Texas A&M University 
in partial fulfillment of the requirements for 
1998-99 UNIVERSITY UNDERGRADUATE RESEARCH FELLOWS PROGRAM 
April 15, 1999 
Approved as to style and content by: 
Dawn M. Boothe 
Department of Veterinary Physiology and Pharmacology 
Susanna Finnell, Executive Director 
Honors Programs and Academic Scholarships 
Fellows Group: Biology I 
ABSTRACT 
Comparitive Study of Four Fluorinated Quinolones in Susceptibility factors on 
Microorganisms. Ketul Patel, $3r. Dawn Boothe) University Undergraduate Research Fellow, 
1998-1999, Texas A&M University, Department of Veterinary Physiology and Pharmacology 
Widely considered in the medical field as the last of the golden anti-microbial drugs, fluorinated 
quinolones provide a "last defense" for the attack on bacterial infections. The drugs are useful for 
treating gram negative and some gram positive infections. Among the advantages of fluorinated 
quinolones are oral dosing, resistance that develops slowly via mutation rather than plasmid 
mediated mutations and high bactericidal activity at low concentrations. All are quinolone 
carboxylic acid derivatives which inhibit bacterial DNA gyrase, a mechanism of action unique 
among the antibacterials. The drugs considered in this study were enrofloxacin, ciprofloxacin, 
difloxacin, and orbifloxacin. Enrofloxacin, difloxacin, and orbifloxacin are veterinary products 
used to treat dermal, respiratory and urinary infections in small animals. Ciprofloxacin, however, is 
a human drug used for similar infections. The human drug, ciprofloxacin, is often cited as effective 
against selected microorganisms in veterinary medicine, while the veterinary drug, enrofloxacin, is 
cited as resistant. As a result, veterinarians often use the human drug. Yet, the chemical structures 
of the drugs suggest that microorganisms should exhibit similar susceptibility patterns. This study 
hopes to prove an equal effectiveness of enrofloxacin and ciprofloxacin. Microbial susceptibility to 
drugs is measured by determining the MIC (Minimum Inhibitory Concentration). The MIC is 
measured based on the growth of the targeted bacteria in increasing concentrations of each drug 
following incubation under standard conditions. A method using microtiter plates containing broth 
was developed to measure concentrations of growth using colorimetric procedures. Comparisons in 
100 bacterial organisms reveal subtle differences in the MIC's between the drugs (based on 
micromolar concentrations) showing relative effectiveness between the organisms. This study 
supports our belief that bacterial susceptibility does not differ among enrofloxacin and ciprofloxacin 
available to the veterinary practitioner. This study also attempts to explain mechanisms of 
resistance in microorganisms found to be resistant to the four fluorinated quinolones. Using 
biochemical techniques, these organisms will then be used to analyze patterns of resistance on a 
cellular level with determination of why the organism is resistant, Searching for patters of 
resistance involves isolating the DNA, PCR reactions for amplification of the DNA, and bacterial 
transformation. 
INTRODUCTION 
Antimicrobials are compounds used to inhibit or kill microbes such as bacteria or 
fungi. Antimicrobial therapy began with the introduction of penicillin in clinical 
laboratories when Alexander Fleming discovered this first antibiotic in 1939. Since that 
time, many new antimicrobials have been identified or created and therefore, improved 
the lives of many. However, a new threat has emerged and affects even the new 
antimicrobials. 
For centuries, the use of living matter to destroy infections and heal wounds has 
been used. However, it was not until after Louis Pasteur's observation of fungi's effect on 
an anthrax organism that the concept of living organisms used as therapy against other 
living organisms developed. Pasteur witnessed the antagonistic effect of other bacteria 
on anthrax. Paul Ehrlich, at the same time, coined the idea of selective toxicity. Through 
extensive research, he found that certain chemicals can have negative effects on some 
organisms and not others. Using bacteria and humans as an example, he found that some 
chemicals harm bacteria but not humans. Combining the two theories, Alexander 
Fleming, after doing research on Penicil!ium notatum, a common fungal contaminant of 
bacterial cultures, accidentally discovered a chemical product produced by the fungus 
that inhibited the growth of other bacteria. This product was then isolated and became 
what we know today as penicillin. 
Penicillin is categorized as a beta-lactam antibiotic. Antibiotics are an 
antimicrobial compound secreted by one microbe that will inhibit another microbe. 
Penicillin inhibits the growth of the bacterial cell wall, which causes the cell to lyse, 
killing the bacterial cell. All cells in a colony are affected in the same manner and the 
colony of bacteria in the patient is destroyed, thereby curing the patient of the infection. 
However, since each colony consists of millions of bacterial cells, there lies the threat of 
resistance developing in the bacteria through mutations. Mutations arise in the DNA of 
newly formed bacteria to encode for a number of different changes that may occur in the 
bacteria to create resistance. For example, in the case of penicillin, a mutation to create 
smaller porin channels through which the drug passes to enter the bacteria, may prevent 
the entry of penicillin and therefore, create resistance. Microorganisms may also develop 
beta-lactamases, enzymes which degrade the drug. The bacterium reproduces, and 
spreads its resistance to its offspring. It also can spread the genetic information to other 
bacterial organisms through plasmids. Soon, the entire colony becomes resistant to 
penicillin. The infection has now multiplied and drug therapy has failed. This often was 
the scenario after the second World War, when over-prescription of antibiotics increased 
the development of antimicrobial resistance. Because of the introduction of foreign 
diseases and infections and the convenience and safety of antibiotics, they were given 
excessively to patients suffering from bacterial infections. Unfortunately, they often 
were given in cases that seemed to be bacterial infections but were not. Obvious 
implications of this in appropriate use of antibiotics is the increased chance for bacterial 
mutations and therefore, increases risk of resistance. Once the bacteria become resistant, 
the drugs are ineffective. Therefore, since the creation of penicillin and the advent of 
bacterial resistance, the pharmaceutical industry has raced to find new, faster, and more 
effective drugs. 
Antimicrobial drugs are classified by their chemical structure, source, or mode of 
action. Many are identified similar to penicillin, that is, as antibiotic compounds secreted 
from microorganisms such as bacteria or fungi that inhibit the growth of other bacteria, 
Others reflect modification of this antibiotic (semisynthetic) and yet, others are 
synthesized in laboratories. They all largely affect crucial and pertinent functions of the 
bacterial cell, initiating biochemical and physiological changes. These functions include 
growth of the cell wall, replication, transcription and translation as well as many others. 
Penicillin and all beta-lactams, as stated earlier, functions by inhibiting the growth of the 
cell wall. Another group of antibiotics recently developed called the fluorinated 
quinolones inhibit a step in the replication process. 
THE FLUORINATED QUINOLONE ANTIMICROBIAL 
Introduction 
Fluorinated quinolones were first introduced in the 1960's with the market of 
nalidixic acid, the first of the quinolones. All of these antibiotics have a four-quinolone 
ring structure and the same mode of action. The basic structure of the fluorinated 
quinolones can be found in Figure 1. Since the creation of nalidixic acid, new and more 
improved quinolones have been created through a series of structural modifications. 
Even though adverse effects of the drugs exist, such as nausea, abdominal discomfort, 
headache, and dizziness, they are rare and the antibiotics are commonly referred to as the 
"last of the golden antimicrobials" because of their safety and efficacy. These antibiotics 
are effective against both gram negative and select gram positive aerobic 
microorganisms, which covers a broad range of bacterial infections. Specifically, they 
are highly effective against gram-negative rods and coccobacilli, including Pseudomona 
aeruginosa and Pasreurella species organisms. Some gram-positive bacteria and acid- 
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Figure 1: This figure represents the basic structure of the fluorinated quinolones. Fluorinated quinolones were first introduced in 
the 1960's with the market of nalidixic acid, the first of the quinolones. All of these antibiotics have a four-quinolone ring 
structure and the same mode of action. Since the creation of nalidixic acid, new and more improved quinolones have been 
created through a series of structural modifications. Even though adverse effects of the drugs exist, such as nausea, abdominal 
discomfort, headache, and dizziness, the antibiotics are commonly referred to as the "last of the golden antimicrobials" (Gilman at 
al, 1059). These antibiotics are effective against both gram negative and select gram positive aerobic microorganisms, which 
covers a broad range of bacterial infections (Ford, 14). Specifically, they are highly effective against gram-negative rods and 
coccobacilli, including Pseudomona aeruginosa and Pasteurella species organisms. Some gram-positive bacteria and acid-fast 
bacteria, such as Staphylococcus aureus and Mycobacteria species organisms, are also susceptible (Hooper, 1993). Fluorinate 
quinolones have offered clinicians orally and parenterally administrable compounds that cover a broad spectrum of bactericidal 
activity. The fluorinated quinolones are effective against a broad range of bacterial infections, including urinary tract infections, 
gastrointestinal infections, sexually transmitted diseases, respiratory tract infections, and osteomyelitis (Acar and Goldstein, 567). 
Another distinguishing characteristic of the quinolones is their ability to diffuse to the site of infection quickly and at large 
concentrations. Furthermore, the mechanism of action for the antibiotics is very unique. 
fast bacteria, such as Staphylococcus aureus and Mycobacteria species organisms, are 
also susceptible. Fluorinated quinolones have provided clinicians drugs which can be 
administered orally and parenterally and which cover a broad spectrum of bactericidal 
activity. Another distinguishing characteristic of the quinolones is their ability to diffuse 
to the site of infection quickly and at large concentrations. The fluorinated quinolones 
are effective in a variety of body systems, including infections by susceptible bacteria in 
the urinary tract, gastrointestinal, reproductive tract (including sexually transmitted 
diseases), respiratory u act, and osteomyelitis. 
Mechanism of Action 
The mechanism of action for the antibiotics is very unique. To explain this, a look 
into the bacterial chromosome is needed. Bacterial DNA has a helical structure 
consisting of two strands. The two strands of DNA must separate for enzymes to 
replicate each strand and produce duplicate strands through a process called semi- 
conservative replication. A typical DNA strand in bacteria is circular and has a 1000-fold 
condensation within the cell. During replication, the circular DNA of bacteria replicates 
and transfers one copy to each daughter cell. Because of the 1000-fold condensation of 
DNA, called supercoiling, the chromosome must unwind for replication. Because of the 
circular structure of DNA, the DNA must be cleaved in order for unwinding to occur. 
The enzyme topoisomerase I is responsible for cleavage of the DNA strand allowing 
initiation of the replication process. Certain enzymes belonging to the topoisomerase I 
family cleave the DNA and separate the two strands. This, in turn, causes "overwinding" 
or excessive positive supercoiling around the point of separation. To relieve this 
mechanical obstacle, the topoisomerase II enzyme family introduces negative 
superhelical twisting. Then, once replication is complete, the newly formed DNA strands 
must be reconnected and returned to its original structure also with the help of these 
enzymes. In particular, one type of topoisomerase II enzyme, DNA gyrase, induces 
negative supercoiling and decatenates DNA circles interlocked. DNA gyrase's 
mechanism of action can be followed in Figures 2 and 3. This is vital for replication 
procedures such as initiation, fork propagation, and termination. The enzyme is also used 
for transcription of certain operons and aspects of DNA repair, recombination and 
transposition. Important functions such as these are prime targets for antibiotic 
development. 
In fact, DNA gyrase is a primary target of the fluorinated quinolones. Although 
most inhibitors of DNA replication bind to DNA and are too toxic to the host, fluorinated 
quinolones were developed to be safe and effective. Afflinity of the host enzymes is 
I/1000' of that of bacterial enzymes, causing "selective toxicity" to the bacteria. They 
are claimed to be "exceptionally potent antibacterial agents" trapping DNA gyrase on 
DNA. They bind to the DNA gyrase enzyme and therefore, the enzyme is ineffective in 
resealing and winding the DNA afler replication. Specifically, DNA gyrase has two 
gyrA subunits. It has been found through previous experimentation that the fluorinated 
quinolones bind to both of these subunits and inhibit the enzyme function. As a result, 
the chromosomal DNA remains fragmented and is eventually degraded by exonucleases. 
This bactericidal effect of fluorinated quinolones is effective in patients with impaired 
humoral or cellular immunity where bacteriostatic antibiotics are inadequate. A visual 
diagram of the mechanism of action of the fluorinated quinolones can be found in Figure 
3. Fluorinated quinolones have also been found to decrease decatenation of interlocked 
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Figure 2: A visual diagram of the mechanism of action of 
DNA gyrase is found in this figure. A typical DNA strand in 
bacteria is circular and has a 1000-fold condensation within 
the cell. During replication, the circular DNA of bacteria 
replicates and transfers one copy to each daughter cell. 
However, because of the 1000-fold condensation, called 
supercoiling, the chromosome must unwind for replication. 
Bacterial DNA has a helical structure consisting of two 
strands. These two strands must separate for enzymes to 
replicate each strand and produce duplicate strands through 
a process called semiconservative replication (Lorian, 670). 
However, because of the circular structure of DNA, the 
DNA must be cleaved in order for unwinding to occur 
(Ford, 14). The enzyme topoisomerase I is responsible for 
cleavage of the DNA strand allowing initiation of the 
replication process. Certain enzymes belonging to the 
topoisomerase I family cleave the DNA and separate the 
two strands (Lorian ). This, in turn, causes "overwinding" 
or excessive positive supercoiling around the point of 
separation. To relieve this mechanical obstacle, the 
topoisomerase II enzyme family introduces negative 
superhelical twisting. Then, once replication is complete, 
the newly formed DNA strands must be reconnected and 
returned to its original structure also with the help of these 
enzymes (Gilman et al, 1058). In particular, one type of 
topoisomerase II enzyme, DNA gyrase, induces negative 
supercoiling and decatenates DNA circles interlocked. This 
is vital for replication procedures such as initiation, fork 
propagation, and termination. The enzyme is also used for 
transcription of certain operons and aspects of DNA repair, 
recombination and transposition. Important functions such 
as these are prime targets for antibiotic development. This 
figure represents the function of DNA gyrase. The enzyme 
is shown as the grey objcet and the black line indicates the 
DNA strand. 
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Figure 3: This figure illustrates the mechanism of action of the fluorinted quinolones. DNA gyrase is a primary target of the 
fluorinated quinolones. Although most inhibitors of DNA replication bind to DNA and are too toxic to the host, fluorinated 
quinolones were developed to be safe and effective (Schaechter et al, 43). They are claimed to be "exceptionally potent antibacterial 
agents" trapping DNA gyrase on DNA (Zhao, 13991). They bind to the DNA gyrase enzyme and therefore, the enzyme is ineffective 
in resealing and winding the DNA after replication. Specifically, DNA gyrase has two gyrA subunits (Gilman et al, 1058). It has 
been found through previous experimentation, that the fluorinated quinolones bind to both of these subunits and inhibit the enzyme 
function (Chi Truong, 85). As a result, the chromosomal DNA remains fragmented and is eventually degraded by exonucleases. This 
bactericidal effect of fluorinated quinolones is effective in patients with impaired humoral or cellular immunity where bacteriostatic 
antibiotics are inadequate (Ford 14). Fluorinated quinolones have also been found to decrease decatenation of interlocked DNA 
circles, impair segregation of replicated chromosomes into daughter cells, and interfere with transcription, DNA repair and 
recombination, in addition to inhibiting replication (Lorian, 670). 
DNA circles, impair segregation of replicated chromosomes into daughter cells, and 
interfere with transcription, DNA repair and recombination, in addition to inhibiting 
replication. 
Bacterial Resistance to Fluorinated Quinolones 
Because resistance is a growing threat to fluorinated quinolones and other 
antibiotics, an insight into clinical cases of resistance may show how resistance patterns 
develop and propagate through bacterial populations. Only recently has previous 
investigations shown that resistance, although slow to develop, occurs through a number 
of ways in the fluorinated quinolones. First, a primary change in the chromosomal DNA 
sequence that codes for the subunits of DNA gyrase may occur. It has been discovered 
that if a double mutation in the chromosomal sequence that encodes for subunit gyrA 
occurs, resistance is conferred to the quinolone antibiotics. A different gyrA subunit may 
result in an inability of the antibiotics to bind to the enzyme, thereby reducing the 
antimicrobial effect. Another possible method of resistance within microorganisms is the 
increased efflux of the drug out of the cell. Once antibiotics accumulate in a bacterial 
cell and begin their effects, the bacteria defensively ejects the drug out of the cell. Yet, 
the amount of antibiotic rejected is usually not ample enough to stop the drug. However, 
a mutation in the regulatory genes that govern the bacterial permeability or efflux 
capacity can alter this amount of antibiotic emitted out of the cell. If an increase in the 
amount of drug ejected from the bacterial cell occurs, an increase in resistance is seen. 
Next, by reducing the levels of quinolone accumulation within the cell, the bacteria may 
also become resistant. This may be done, as discussed, by efflux of the drug out of the 
cell, or by degrading the antibiotic. A mutation may occur in the bacterial "immune" 
system that allows the bacteria to detect and degrade foreign objects. This may lead to 
the detection and degradation of fluorinated quinolones and thus, reduce its amount in the 
bacteria. 
Host factors and antimicrobial efficacy can be responsible for the effectiveness of 
fluorinated quinolones. First, the bioavailability of the drug will effect how must drug 
reaches the site of infection. Once a drug is administered orally, the drug is absorbed 
through the gastrointestinal tract. The amount of drug absorbed determines the level of 
bioavailability, which is the amount of drug at the site of infection. If large quantities of 
the drug are absorbed through the small intestinal mucosa, more of the drug can reach its 
destination. On the other hand, less absorption of the drug leads to lower efficacy. Host 
factors that determine the amount of drug absorption include environmental pH and 
temperature. These will also impact the site of infection. Because the pH at the site of 
infection is lower than other areas of the body and because these drugs are weak bases, 
the antibiotic may be altered (ionized) when introduced to the infection site. Also, the 
increased temperature that usually accommodates a bacterial infection may prove to have 
beneficial effects on the fluorinated quinolones. Inflammation at an infectious site 
usually means an increase in blood flow to the area, which would also increase thc 
amount of drug flow to the area and therefore, immediate results. However, 
accumulating inflammatory debris and fibrous tissue may be deposited in abscesses and 
this may have detrimental effects. If the area of infection has become too inflammed, it 
would be more difficult for the drug to reach the infection and therefore, reduce drug 
penetration. Decreased blood flow may also decrease oxygen, rendering the site 
anaerobic and decreasing the effect of antimicrobials as well as the host immune system. 
BACKGROUND 
The four fluorinated quinolones of interest in this study were enrofloxacin, 
ciprofloxacin, orbifloxacin, and difloxacin. All of the antibiotics, with the exception of 
ciprofloxacin, are licensed to be used in veterinary clinics against susceptible 
microorganisms. Ciprofloxacin has been approved for usage in humans but not in 
animals. The author would like to acknowledge the supplier for these antibiotics, Bayer 
Corporations, Fort Dodge Animal Health, and Shering-Plough Animal Health. 
Enrofloxacin is better known as Baytril to the practicing veterinarian. Its 
chemical structure can be found in Figure 4. Enrofloxacin, as stated, is a veterinary drug 
that has been in used for over ten years. 
The only human drug in our study was ciprofloxacin. Refer to the chemical 
structure in Figure 5. It was received in the form of a monohydrochloride monohydrate 
salt, ciprofloxacin hydrochloride, which is how it is supplied for in vitro diagnostic use. 
Its molecular weight is 385. 8 grams and is highly water soluble at 3. 5 g per 100 ml at the 
temperature of 25'C. Cipro Diagnostic Powder was stored at the recommended 
temperature of below 30'C. Created solely for human purposes, it is not licensed to be 
used by veterinarians even though usage on animals does occur, 
Similar to enrofloxacin, orbifloxacin and difloxacin are veterinary drugs. They 
are el'fective against animal bacterial infections. Their structures can be found in Figure 
6. Unlike enrofloxacin and ciprofloxacin, these two antibiotics were recently developed 
and therefore, little attempt has been made to study them, Information concerning 
susceptibility patterns and effectiveness of the drugs is yet to be determined with the help 
of this study. 
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Figure 4: This is the chemical structure of enrofloxacin. Enrofloxacin is better known as Baytril to the practicing veterinarian. 
Enrofloxacin, as stated, is a veterinary drug that has been used for over ten years now. 
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Figure 5: This figure visually shows the chemical structure of ciprofloxacin. The only human drug in our study was ciprofloxacin. It was 
received in the form of a monohydrochloride monohydrate salt, ciprofloxacin hydrochloride, which is how it is found for in vitro 
diagnostic use. Its molecular weight is 385. 8 grams and is highly water soluble at 3. 5 g per 100 ml at the temperature of 25'C. Cipro 
Diagnostic Powder was stored at the recommended temperature of below 30'C (Package insert, 1998). Created solely for human 
purposes, it is not licensed to be used by veterinarians even though usage on animals does occur. 
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Figure 6: This figure illustrates the chemical structures of difloxacin and orbifloxacin together. Similar to enrofloxacin, 
orbifloxacin and difloxacin are veterinary drugs. They are effective against animal bacterial infections. Unlike enrofloxacin and 
ciprofloxacin, these two antibiotics were recently developed and therefore, little attempt has been made to study them. Information 
concerning susceptibility patterns and effectiveness of the drugs is yet to be determined with the help of this study. 
The effectiveness of drugs can be compared based on susceptibility patterns. 
Susceptibility patterns help show how drugs are effective against bacteria with varying 
concentrations of drug. A test typically used for susceptibility pattern determination is 
the tube or plate dilution method. This test provides a quantitative comparison of 
antimicrobials relating the amount of drug necessary to inhibit microbial growth. The 
quantifiable number is called the minimum inhibitory concentrations (MIC) and is unique 
for each drug against each microorganism. The MIC is the lowest concentration of drug 
needed to inhibit visible growth of the organism. It can be determined by first, creating 
tube or plate dilutions of the drug in serially decreasing concentrations. Then, an equal 
and standard number of organism is inoculated in the tubes or the plate. After a standard 
incubation period, the tube or plate well with the lowest concentration and no visible 
growth is determined to be the MIC. For example, assume an infection with 
Pseudomonas spp. A tissue sample collected from the site of infection will be sent to the 
lab and the organism will be isolated. It will be exposed to increasing concentrations of 
several drugs, If the lab studies find that the MIC of enrofloxacin is 0. 5 irg/ml, then this 
is the concentration at which no observable growth is seen in the laboratory environment. 
This, then would be the concentration of enrofloxacin to achieve in tissues that are 
infected. If the concentration of drug at the site is lower, at 0. 25 lrg/ml for instance, then 
bacterial growth will not be inhibited at the site of infection. In the test tube containing 
25 Itg/ml, growth of the organism will be seen. In contrast, if the concentration of the 
drug is higher, at I ltg/ml, then bacterial growth will not be seen. The MIC value has 
practical purposes for the veterinarian. It allows the clinician to identify at which 
concentration the drug is effective in vitro, and this can be used as an estimation for 
administratable doses. Note that the MIC only indicates the point at which the bacterial 
growth is inhibited. The minimum bactericidal concentration (MBP) is the minimum 
point at which the drug not only inhibits but also kills all of the bacteria, It can be 
determined by growing the tubes or plate wells with no visible signs of bacterial growth 
on agar plates. The plate with the smallest concentration that yielded no growth when 
inoculated on a blood agar plate contains the MBC. 
From the MIC data, an applicable drug concentration can be calculated by 
comparing the MIC value to the breakpoint MIC value. The breakpoint MIC is the 
concentration reached safely within the patient after administration of the recommended 
dosing regimen. This value is unique to each host and drug but is not unique to each 
organism. In other words, a breakpoint MIC of 2 ltg/ml for enrofloxacin in cats holds 
true for all organisms and all cats administered enrofloxacin. Every time the cat is given 
the recommended dosing regimen, it will achieve a 2 lig/ml concentration of enrofloxacin 
in vivo. For an organism to be considered susceptible to a drug, its MIC ideally is less 
than the breakpoint MIC. For example, the MIC of enrofloxacin against a certain strain 
of Pseudomonas aeruginosa in a dog may equal 0. 5 Iig/ml. The breakpoint MIC for 
enrofloxacin in a dog is 2 Itg/ml, meaning that the recommended dose when administered 
to the patient will achieve 2 lig/ml. This is four times greater than the MIC of the 
organism causing infection, and thus, enrofloxacin should be effective against this 
organism. Therefore, veterinarians, by knowing the breakpoint MIC and the MIC of the 
bacteria, can conclude of how effective a certain antimicrobial is against a specific 
bacterial strain can be seen. 
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Breakpoint MIC values are crucial in determining susceptibility patterns in 
antimicrobials by comparing the values to MIC values. Susceptibility patterns refer to 
the organism's response to a specific drug concentration. This concentration is the MIC. 
If the MIC of an antimicrobial is less than the breakpoint MIC, then the bacteria is 
labeled as susceptible or S. In this case, the drug was effective. The bacteria is 
categorized as resistant or R if the MIC of the infecting organism is greater than the 
breakpoint MIC. This would result in the organism surviving even after the 
recommended amount of drug is given. The call for a new drug would be in order in 
these cases. Breakpoint MIC values are literature values taken from the Physicians Desk 
Reference, but can also be found in professionally fixed labels or the laboratory providing 
the microbiological data. 
This experiment attempts to compare the efficacy of the four fluorinated 
quinolones mentioned: enrofloxacin, ciprofloxacin, orbifloxacin, and difloxacin. MIC 
values from various clinical bacterial cases were determined for a broad range of 
microorganisms and then compared to determined efficacy patterns. 
HYPOTHESIS AND OB JECTIVES 
The objectives for the experiment are three-fold. First, MIC ranges will be 
determined for each microorganism and each drug. These will be found by determining 
the highest and lowest MIC values and organizing them into a range. Furthermore, 
MIC9Qs (the MIC at which 90'/0 of the organism are inhibited) of selected bacteria 
causing infection in veterinary patients for ciprofloxacin, enrofloxacin, orbifloxacin, and 
difloxacin will be determined. The selected bacteria for which MIC&a values are found 
are those in which ten or more different species were collected. Next, a comparison of 
the MICs of infecting bacteria for all four fluorinated quinolones will be made. This will 
be done by determining the proportions of organisms that are resistant versus susceptible 
to each drug. Finally, since the organisms were received from clinical cases across the 
nation, a demographic comparison will be made. Consideration will be given to where 
the organisms were collected from, the type of host, and the bacterial infection from 
which the organisms were found in. 
As evident in the chemical structures, enrofloxacin and ciprofloxacin are very 
similar. Both antibiotics exhibit similarities in function, mechanism, and structure, with 
the only structural difference being an extra methyl group on enrofloxacin, Therefore, 
because of the similarities between the two drugs, our hypothesis is that both drugs are 
equally effective. We suspect they will exhibit similar susceptibility patterns. However, 
our expanded hypothesis is that resistance patterns will also be similar across all the 
fluorinated quinolones. 
MATERIALS AND METHODS 
Since this project works closely with infectious bacteria, a strict procedure of 
sterile laboratory technique must be closely followed. A procedure involving utmost care 
and management of the microorganisms was developed considering the guidelines set 
forth by the National Committee on Clinical Laboratory Standards (NCCLS). These 
guidelines were strictly followed and incorporated into every aspect of the procedure. In 
addition, aseptic technique was prescribed for techniques not only directly dealing with 
the organisms, but also with the rest of the procedure. All equipment used was 
autoclaved to achieve sterility. The procedure spans a number of days since isolation and 
growth of bacterial colonies requires multiple days. Furthermore, to ensure accuracy, 
drug solutions must be used the same day they are created. This would assure accurate 
readings because the drugs are prevented from reacting with the media they are prepared 
in over time and are unable to lose efficacy. Because consistency is very important, each 
drug was created in the same manner and treated equally. In fact, because the procedure 
was repeated numerous times, the procedure was conducted uniformly, rigorously 
adhering to the procedure carefully. 
Upon agreement with Antech Diagnostics and Antech East Diagnostics, Inc. 
located in California and New York, respectively, bacterial organisms were received in 
transportable culturette tubes (BBL Culturette Systems), via Airborne Express next day 
delivery service. Culturettes are standard transporting mechanisms for bacteria colonies. 
The device has a cotton swab that is used to pick up a bacterial colony. The swab is place 
back into the culturette device and the yellow end containing bacteria supporting media is 
crushed to release the growing media for the bacteria. Thc bacterial cultures are able to 
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Figure 7: This figure illustrates a culturette tube, a blood agar plate, and the technique for streaking. Culturettes are standard 
transporting mechanisms for bacteria colonies. The device has a cotton swab that is used to pick up a bacterial colony. The swab is 
place back into the culturette device and the yellow end containing bacteria supporting media is crushed to release the growing 
media for the bacteria. The bacterial cultures are able to survive in the tubes for at most, three to four days without inducing 
harmful effects to the bacteria. Once the culturettes arrived, they were checked to see if the end was crushed and the media 
released. Once this was confirmed, they were streaked for isolation on (SIZE) blood agar plates. Blood agar plates are used to 
grow a broad range of gram negative and gram positive bacteria. It is partially made of sheep blood to provide extra nutrients for 
hard-to-grow and slow-growing bacteria. 
With these blood agar plates, the organisms are streaked for isolation. The cotton swab of the culturette is removed and streaked, 
in a smooth, even manner, across half of the plate. Then, the swab is cut and placed in a tryptose agar bath. An inflammed loop is 
used to isolate the colonies by streaking through the already streaked portion of the plate and continuing to spread the bacteria onto 
the unstreaked part of the plate. Only half of the unstreaked portion of the plate is used, essentially only using one quarter of the 
plate. The loop is then placed in the flame again to sterilize it. Then, the rest of the plate is streaked with the same procedure as 
before, to isolate individual colonies. The plate is then placed in an incubator of temperature 37' C for 24 hours. The cotton swabs 
are placed in tryptose agar tubes to allow for sustained growth on the swab in case no growth is seen on the plates. They are also 
incubated at the same temperature for 24 hours. 
survive in the tubes for at most, three to four days without inducing harmful effects to the 
bacteria. Once the culturettes arrived, they were checked to see if the end was crushed 
and the media released. Such organisms were not studied because of the risk of bacterial 
contamination. Organisms were streaked for isolation on (SIZE) blood agar plates. 
Blood agar plates are used to grow a broad range of gram negative and gram positive 
bacteria. The agar contains sheep blood to provide extra nutrients for hard-to-grow and 
slow-growing bacteria. 
With these blood agar plates, the organisms are streaked for isolation. Figure 7 
illustrates this concept. The cotton swab of the culturette is removed and streaked, in a 
smooth, even manner, across half of the plate. Then, the swab is cut and placed in a 
tryptose agar bath. An inflamed loop is used to isolate the colonies by streaking through 
the already streaked portion of the plate and continuing to spread the bacteria onto the 
unstreaked part of the plate. Only half of the unstreaked portion of the plate is used, 
essentially only using one quarter of the plate. The loop is then placed in the flame again 
to sterilize it. Then, the rest of the plate is streaked with the same procedure as before, to 
isolate individual colonies. The plate is then placed in an incubator of temperature 37' C 
for 24 hours. The cotton swabs are placed in tryptose agar tubes to allow for sustained 
growth on the swab in case no growth is seen on the plates. They are also incubated at 
the same temperature for 24 hours. 
The next day, stock solutions of the four fluorinated quinolones are made using 
sterile glassware and aseptic techniques. First, five milligrams of each drug was 
accurately weighed using an analytical balance and dissolved in ten milliliters of 
methanol to give a 500 tig/ml stock solution, labeled stock solution A for discussion 
purposes. Each of the drugs is dissolved in this same manner to ensure accurate readings. 
Once the drugs are dissolved, a 100 ttg/ml stock solution (stock solution B) is made using 
Mueller-Henton broth. Mueller-Henton was pre-made beforehand using a powdered 
stock The broth is a liquid medium for bacterial growth. The equation used to determine 
how to prepare the 500 ltg/ml stock solution is: 
Equation 1 Vi = Cz Vi 
where Ci equals the initial concentration of stock solution A (500 )tg/ml), Vi is the 
unknown volume to be taken from stock solution A (X), Ci is the desired concentration in 
stock solution B (100 pg/ml), and Vi is the desired volume of Mueller-Henton broth 
stock solution B (5 mls). Using the formula, one milliliter of the methanol stock solution 
A is taken and added to four milliliters of Mueller-Henton broth. This results in a 1:5 
dilution of stock solution A. Five milliliters were created to ensure enough of the stock 
to produce multiple dilutions. Once this solution is mixed, the initial tube dilution is 
made. Using the same formula, it was determined that 640 ltL of stock solution B added 
to 1360 NL of Mueller-Henton broth would produce the first desired dilution 
concentration, which was 32 ltg/mh From this initial dilution, subsequent dilutions 
decreased by one-half. This meant that to produce the next dilution of 16 ttg/ml, one 
milliliter of the first dilution was taken and added to one milliliter of Mueller-Henton 
broth. Continuing this process nine times results in all dilutions for one drug. The same 
procedure is used for all four fluorinated quinolones. 
Once the dilutions have been made, the sterile microtiter plate (Nunc V96 
Polypropylene plate) can be created. Refer to Figure 9 for a diagram of the plate. The 
microtiter plate contains 96 wells, each capable of holding 150 tih With one plate per 
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Figure 8: A test typically used for susceptibility 
pattern determination is the tube or plate dilution 
method (Boothe 1998). This test provides a 
quantitative comparison of antimicrobials relating 
the amount of drug necessary to inhibit microbial 
growth. The quantifiable number is called the 
minimum inhibitory concennations (MIC) and is 
unique for each drug against each microorganism. 
The MIC is the lowest concentration of drug needed 
to inhibit visible growth of the organism (Boothe, 
1998). The MIC value has practical purposes for the 
veterinarian. It allows the clinician to see at which 
concentration the drug is effective in vitro, which 
can be used as an estimation for administratable 
doses. Itcan be determined by first, creating tube or 
plate dilutions of the drug in serially decreasing 
concentrations. Then, an equal and standard number 
of organism is inoculated in the tubes or the plate. 
After a standard incubation period, the tube or plate 
well with the lowest concentration and no visible 
growth is determined to be the MIC. 
drug, four plates are created. Each dilution is placed horizontally across the plate, 
beginning with the 32 Itg/ml concentration and ending with the 0. 0625 lig/ml 
concentration. Every row is filled horizontally in this manner. The last column is for the 
negative blank. In these well, 120 Iil of Mueller-Henton broth is pippetted. The last row 
will contain the positive blank. 
For preparation of the microorganism, the streaked plates are removed from the 
incubator. One isolated colony is removed and a standard solution is made to mediate the 
same number of organisms for each plate. This standard is made by inoculating the 
colony in two milliliters of saline solution using a cotton swab. The standard is then 
checked for a standard 0. 5 Macfarland turbidity. The Macfarland system is used to 
characterize turbidity in bacterial suspensions. The more cloudy the suspension, the more 
the bacterial colonies present and the greater the Macfarland unit. The lower the unit 
indicates a clearer solution and a lower number of bacterial colonies. A 0. 5 Marfarland 
turbidity was used because standard MIC determining procedures require this standard. 
For all the organisms to be tested for MIC determination, a 0. 5 Macfarland saline 
standard was made. Then, again according to standard MIC determining procedures, one 
milliliter of this solution was diluted in 24 milliliters of sterilized water. This uniformly 
suspended 1:24 dilution was then added to the microtiter plate in equal quantities as the 
drug. Therefore, 120 p, l of this solution was added to each well horizontally. Each row 
contained a different microorganism, using seven rows. In the final row, plain Mueller- 
Henton broth was added to create the positive control. This control was tested for no 
growth since only the drug and the broth were added. The negative control, however, 
was used to indicate growth of the microorganisms as it contained only the broth and the 
organism. 
Once the plate is created, they are covered with parafilm to avoid evaporation of 
the contents in the heated incubator. The plates are then placed in the same incubator 
used before to grow the microorganisms, at 37'C and for approximately 24 hours. After 
the incubation time, the plates were removed and read by visually observing the MIC in 
the microtiter plate using a mirror. Once the parafilm is removed, the plates were placed 
on a stand with a positioned mirror at the base. By looking at the mirror, readings were 
taken Irom observing below the plate. The recorded value of MIC was the well with the 
lowest concentration of no visible growth. These MIC values will be compared 
according to the genus and species of the microorganism. The percentage of resistant 
organisms will be found and comparisons on the types of hosts and geographical place of 
origin of the infections will be made. 
RESULTS 
The results are categorized into different tables. The first table simply shows the 
MIC values found for each organism to each fluorinated quinolone. The number of 
organisms tested was 63, all of which were either gram negative (n = 46) or gram positive 
(n = 17). The different organisms were Escheri chia coli (n = 13), Proteus mi rabolis (n = 
6), Pseudomonas species (n = 16), Staphylococcus species (n = 8), Streptococcus species 
(n = 9) and miscellaneous isolates consisting of Klebsiella pneumoniae, Actinomyces, 
pyogenes, Bacillus sp. , Enterobacter sp. , Bordetella bronchiseptica, Pasteurella 
multocida, and Serratia sp. (n = 11). Also, of the 63 microorganisms collected and 
studied, most were collected Irom dogs (n = 43), some from cats (n = 7), some from birds 
(n = 6), and some from horses (n = 4). Sites of location of bacterial infection can also be 
compared using Table 1. Bacterial organisms were taken from urinary tract infections (n 
= 18), from ear infections (n = 9), from nasal infections (n = 4), and from other 
infections, such as tracheal, joint, or hip (n = 8) with the rest unindicated. The 
geographical locations of the bacterial infections can also be compared. More 
microorganisms were collected from the western half of the United States (n = 8) than 
from the eastern half (n = 21). Some were collected from either the Bryan/College 
Station community or the Houston community (n = 8). The rest of the organisms were 
not indicated geographically as to where the sample was taken. The susceptibility 
patterns were determined by comparing the experimentally determined MIC value with 
the breakpoint MIC for each antibiotic. If the experimental value is higher than the 
breakpoint value, the organism is categorized with an R for resistance. An S is 
designated for organisms that have experimental MICs lower than the breakpoint MIC. 
Designations of S and R are given to the MIC values in Table 2. Table 3 shows the MIC 
ranges of the bacteria and MIC9a values of select bacteria. The MICsa of Escherichia coli 
for ciprofloxacin was 0. 0625, ~0. 031 for enrofloxacin, 0. 25 for difloxacin and 0. 125 for 
orbifloxacin. Table 4 shows the percent of resistant organisms overall and for each 
antimicrobial. 
Table 1: Microorganism MIC results with the four fluorinated quinolones. 
GENUS SPECIES Origin Animal Location 
Enro 
~RIS 
Cipro Orbi Di 
ENTERQDAcTER 
BORDETELLA 
KI. EHSI ELLA 
KLEBSIEI. I A 
ACTINOMYCES 
BACILLUS 
ENTEROBACTER 
ESCHERICHIA 
ESCHERICIHA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
EscHERICI HA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
KLEBSIEI LA 
KLEBSIELLA 
PASTEURELLA 
PROTFUS 
PROTEUS 
PROTEUS 
PROTEUS 
PROTFUS 
PROTEUS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUDOMONAS 
PSEUOOMONAS 
PSF. UI&OMONAS 
PSEUDOMONAS 
PSEUDO MONAS 
SP 
BRONCHISEPTICA 
PNEUMONIAB 
PVBUMONIAE 
PYOGENES 
SP. 
AEROGENES 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
COI I 
COL I 
COLI 
COLI 
COLI 
COLI 
COL& 
PNEUMONIAE 
LIULTOCIOA 
LBBABGLIS 
PIIBABILIS 
MIBABILIS 
MIBABOLIS 
MIBABGLIS 
M IBABOLIS 
AEBUGINOBA 
AERUGINOSA 
AEBGGINGSA 
ABBUGINOSA 
AERVGINGSA 
AERGGINGSA 
ABRUGINOSA 
ABRUGINOSA 
SP 
SP 
SP 
SP 
SP 
College Station, TX 
College Station, TX 
College Station, TX 
College Station, TX 
College Station, TX 
Southern CA 
Fayetteville, GA 
N/A 
N/A 
N/A 
N/A 
California 
California 
California 
Fayettevdle, GA 
Marietta, GA 
N. Charles-ton, SC 
Frazer, PA 
College Station, TX 
Reisters-tovpn, MD 
Sante Fe, NM 
N/A 
N/A 
N/A 
California 
NY 
Fayetteville, NC 
Brooklyn, NY 
Southhold, NY 
N/A 
Maiyaro-neck, NY 
Fayetteville, GA 
Brooklyn, NY 
Garden City, NY 
Houston, TX 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
Avian 
Canine 
Equine 
Avian 
Canine 
Canine 
Canine 
Feline 
Canine 
Canine 
Canine 
Avian 
Canine 
Canine 
Canine 
Canine 
N/A 
Canine 
Canine 
Canine 
Canme 
Avian 
Feline 
Canine 
Canine 
Canine 
Canine 
Canine 
Canine 
Canine 
Canine 
Cantne 
Feline 
Canine 
Avian 
Canine 
Canine 
Feline 
Canme 
Canme 
Canine 
Canine 
CanIne 
Canine 
Nasal 
Tracheal 
Joint 
Nasal 
Nasal 
N/A 
Colon 
Urine 
Urine 
Urine 
Feces 
Feces 
Urine 
Urine 
Colon 
Urine 
Mandibular pin 
Hip 
Prostate 
N/A 
Urine 
N/A 
Nasal 
Feces 
Ear 
Ear 
N/A 
Ear 
Tracheal 
Ear 
Ear 
N/A 
Ear 
Vaginal 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
&0, 0625 
&0. 0625 
0. 0625 
0. 0625 
&0. 0625 
0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
(0. 03125 
(0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
0. 03125 
&0. 03125 
0. 0625 
&0. 03125 
4 
0. 03125 
0. 5 
0. 0625 
0. 0625 
0. 03125 
0. 015625 
0. 25 
&0. 03125 
0. 015625 
&0. 03125 
0. 125 
&0. 03125 
&0. 03125 
0. 125 
&0 03125 
0. 015625 
0. 0625 
0. 25 
0. 125 
0. 125 
0. 5 
0. 125 
0. 125 
0. 125 
0. 125 
&0. 0625 
&0. 0625 
&0. 0625 
&0. 0625 
&0. 0625 
0. 0625 
0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
&0. 03 125 
0. 03125 
&0. 03125 
0. 0625 
&0. 03125 
4 
&0. 03125 
0. 0625 
0. 03125 
0. 0625 
&0. 03125 
0. 015625 
0. 25 
&0. 03125 
0. 015625 
&0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
0. 125 
&0. 03125 
0. 015625 
0. 125 
0. 125 
0. 0625 
0. 0625 
0. 5 
0. 125 
0. 0625 
0. 0625 
0. 0625 
0. 125 
&0. 0625 
&0. 0625 
&0. 0625 
0. 0625 
0. 125 
0. 0625 
&0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
0. 03125 
0. 03125 
0. 03125 
0. 125 
&0. 03125 
&16 
0. 125 
1. 0 
0. 5 
&0. 03125 
0. 25 
0. 0625 
1 
0. 03125 
0. 03125 
&0. 03125 
0. 5 
0. 125 
0. 125 
0. 5 
&0. 03125 
0. 03125 
0. 25 
0. 5 
0. 25 
0. 25 
1 
0. 25 
0. 25 
0. 25 
0. 25 
0. 25 
0. 03125 
&0. 03125 
&0. 03125 
&0. 03125 
&0 03125 
&0. 03125 
&0. 03125 
0. 0625 
0. 125 
0. 0625 
0. 25 
&0. 03125 
&16 
0. 0625 
2. 0 
0. 125 
&0. 03125 
0. 25 
0. 0625 
0. 5 
&0. 03125 
0. 03125 
&0. 03125 
0. 125 
0. 0625 
0. 0625 
0. 25 
&0. 03125 
0. 015625 
0. 25 
2 
1 
1 
4 
1 
I 
0. 5 
1 
GENUS 
PSEUDOMONAS 
SE. RRATIA 
STAPHYLOCOCCUS 
STARHYI. ococcus 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STAPHYI. OCOCCUS 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STREPTOCOCCUS 
STREPTOCOCCUS 
(BETA) 
STREPTOCOCCUS 
(BETA) 
STREPTOCOCCUS 
(BE I A) 
STREPTOCOCCUS 
STREPTOCOCCUS 
STREPTOCOCCUS 
STREPTOCOCCUS 
(GAMMA) 
STREPTOCOCCUS 
(GAMMA) 
SPECIES 
AERUOINOSA 
SP. 
INTERMEDIUS 
AURPLIS 
INTERMEDIUS 
INTERMEDIUS 
INTERMEDIUS 
INTERMEDIUS 
SP 
SP 
SP. 
SP. 
SP. 
SP 
EQUI 
EQUI 
SP 
SP 
SP 
Origin 
St. Paul, MN 
Greenwich village, 
NY 
N/A 
California 
California 
Marietta, GA 
Glenn Dale, MD 
Lebanon, NJ 
N/A 
N/A 
N/A 
Fayetteville, GA 
N/A 
N/A 
Albequerque NM 
Central TX 
N/A 
Camden, SC 
Madison, AL 
Animal 
Canine 
Feline 
Canine 
Avian 
Canine 
Canine 
Feline 
Canine 
Avian 
Avian 
Canine 
Canine 
Canine 
Canine 
Equine 
Equine 
Canine 
Equine 
Feline 
Location 
Urine 
Alveoli 
Ear 
N/A 
Vaginal 
Ear 
Tympanic bullae 
Osteomyelitis of 
femur 
N/A 
N/A 
Urine 
N/A 
N/A 
Ear 
Uterine 
Uterine 
N/A 
N/A 
N/A 
Enro 
1 
&0. 03125 
0. 0625 
0. 125 
0. 03125 
&0. 03125 
0. 03125 
&0. 03125 
8 
1 
0. 125 
&0. 03125 
0. 03125 
0. 125 
&0. 03125 
&0. 03125 
0. 5 
0. 03125 
0. 0625 
0. 125 
0. 125 
0. 03125 
0. 03125 
0. 03125 
&0. 03125 
0. 25 
0. 25 
0. 5 
0. 25 
0. 125 
&0. 03125 
8 
1 
0. 5 
&0. 03125 
&16 
1 
1. 0 
&0. 03125 
&0. 03125 0. 25 
0. 125 
&0. 03125 
&0. 03125 
1 
0. 0625 
0. 5 
&0. 03125 
0. 03125 
2 
0. 5 
0. 0625 0. 125 
R~l/ 
Cipro Orbi 
1 4 
&0. 03125 &0. 03125 
Di 
2 
&0. 03 125 
0. 125 
0. 25 
0. 5 
0. 25 
0. 25 
&0. 03125 
&16 
0. 5 
0. 25 
&0. 03125 
0. 0625 
0. 25 
&0. 03125 
0. 0625 
2 
0. 25 
0. 5 
Table 2: The in vitro susceptibility patterns of microorganisms. 
GENUS SPECIES 
Euro 
Results /ml 
Cipro Orbi Di 
BACILLUS 
ENTEROBA CTER 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESCHERICHIA 
ESHERICHIA 
KLEBSIELLA 
KLEBSIELLA 
PASTEURELLA 
PROTEUS 
PROTEUS 
PROTEUS 
PROTEUS 
PROTEUS 
PROTEUS 
PSEUDOMONAS 
PSEUD OMONA S 
PSEUD OMONA S 
SPECIES 
AEROGENES 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
COLI 
PNEUMOÃIAE 
MULTOCIDA 
MIRABOLIS 
MIRABILIS 
MIRABILIS 
MIRAB OLIS 
MIRABOLIS 
MIRABOLIS 
AER UGINOSA 
ALRUGINOSA 
A ER UG JNOSA 
0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0, 03125 S 
0. 03125 S 
&0. 03125 S 
0. 0625 S 
&0. 03125 S 
4 R 
0. 03125 S 
0. 5 S 
0. 0625 S 
0. 0625 S 
0. 03125 S 
&0. 03125 S 
0. 25 S 
&0. 03125 S 
0. 03125 S 
&0. 03125 S 
0. 125 S 
&0. 03125 S 
&0. 03125 S 
0. 0625 S 
0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
0. 03125 S 
&0. 03125 S 
0. 0625 S 
&0. 03125 S 
4 R 
&0. 03125 S 
0. 0625 S 
0. 03125 S 
0. 0625 S 
&0. 03125 S 
&0. 03125 S 
025 S 
&0. 03125 S 
0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03 125 S 
0. 125 S 
0. 0625 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
0. 03125 S 
0. 03125 S 
0. 03125 S 
0. 125 S 
&0. 03125 S 
&16 R 
0. 125 S 
1. 0 S 
0. 5 S 
&0. 03125 S 
025 S 
0. 0625 S 
1 S 
0. 03125 S 
&0. 03125 S 
&0. 03125 S 
0. 5 S 
0. 125 S 
0. 125 S 
025 S 
0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
0. 0625 S 
0. 125 S 
0. 0625 S 
025 S 
&0. 03125 S 
&16 R 
0. 0625 S 
2. 0 S 
0. 125 S 
&0. 03125 S 
0. 25 S 
0. 0625 S 
0. 5 S 
&0. 03125 S 
&0. 03125 S 
&0. 03125 S 
0. 125 S 
0. 0625 S 
0. 0625 S 
GENUS 
PSEUDOMONAS 
PSEUDOMONAS 
PSUEDOMONAS 
PS UEDOMONA S' 
PSUEDOMONAS 
PSUEDOMONAS 
PSUEDOMONA S 
PSUEDOMONA S 
PSUEDOMONAS 
PSUEDOMONAS 
PS UEDOMONA S 
PSUEDOMONA S 
PSUEDOMONA S 
SERRA TIA 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STAPHYLOCOCCUS 
STREP. 
STREP. (BETA) 
STREP. (BETA) 
STREP. (BETA- 
HEMOL YTIC) 
SPECIES 
AER UGINOSA 
AER UGINOSA 
AER UGINOSA 
AER UGINOSA 
A ER UGINOSA 
SP 
SP 
SP 
SP 
SP 
SP 
SP 
AER UGINOSA 
SP. 
INTERMEDIUS 
A UREUS 
INTERMEDIUS 
INTERMEDIUS 
INTERMEDIUS 
IN TERMEDIUS 
SPECIES 
SPEC. 
Euro 
0. 125 S 
&0. 03125 S 
&0. 03125 S 
0. 0625 S 
0. 25 S 
0. 125 S 
0. 125 S 
0. 5 S 
0. 125 S 
0. 125 S 
0. 125 S 
0. 125 S 
1 S 
&0. 03125 S 
0. 0625 S 
0, 125 S 
0. 03125 S 
&0. 03125 S 
0. 03125 S 
&0. 03125 S 
8 R 
1 S 
0. 125 S 
&0. 03125 S 
0. 03125 S 
0. 125 S 
Results 
Cipro 
0. 125 S 
&0. 03125 S 
&0. 03125 S 
0. 125 S 
0. 125 S 
0. 0625 S 
0. 0625 S 
0. 5 S 
0. 125 S 
0. 0625 S 
0. 0625 S 
0. 0625 S 
1 S 
&0. 03125 S 
0. 125 S 
0. 125 S 
0. 03125 S 
0. 03125 S 
0. 03125 S 
&0. 03125 S 
8 R 
1 S 
0. 5 S 
&0. 03125 S 
&0. 03125 S 
0. 125 S 
Orbi 
0. 5 S 
&0. 03125 S 
&0. 03125 S 
025 S 
0. 5 S 
025 S 
025 S 
1 S 
025 S 
0. 25 S 
0. 25 S 
025 S 
4 R 
&0. 03125 S 
025 S 
025 S 
0. 5 S 
0. 25 S 
0. 125 S 
&0. 03125 S 
&16 R 
1 S 
1 S 
&0. 03125 S 
0. 125 S 
0. 5 S 
Di 
025 S 
&0. 03125 S 
&0. 03125 S 
0. 25 S 
2 S 
1 S 
1 S 
4 R 
1 S 
1 S 
0. 5 S 
1 S 
2 S 
&0. 03125 S 
0. 125 S 
0. 25 S 
0. 5 S 
025 S 
0. 25 S 
&0. 03125 S 
&16 R 
0. 5 S 
025 S 
&0. 03125 S 
0. 0625 S 
0. 25 S 
GENUS SPECIES Results /ml: 
Euro Cipro Orbi Di 
STREPTOCOCCUS 
STREPTOCOCCUS 
STREPTOCOCCUS 
STREPTOCOCCUS 
(GAMMA) 
STREPTOCOCCUS 
(GAMMA) 
EQUI 
EQUI 
0. 0625 S 0. 0625 S 
&0. 03125 S &0. 03125 S 
&0. 03125 S &0. 03125 S 
0. 5 S 1 S 
0. 03125 S 0. 0625 S 
&0. 03125 S &0. 03125 S 
0. 03125 S 0. 0625 S 
2 R 2 S 
0. 5 S 0. 25 S 
0. 125 S 0. 5 S 
Table 3: MIC ranges and MIC9Q determinations of the microorganisms studied. 
Staphylococcus 
spp 
Staphylococcus 
aureus 
Staphylococcus 
intermedi us 
Streptococcus 
spp. 
Escherichia 
coli 
Klebsiella spp 
Proteus spp 
Enterobacter 
spp 
Bacillus spp. 
Pseudomonas 
spp. 
Pseudomonas 
aerugi nosa 
Pasteurella 
multocida 
Serratia spp. 
MIC 
Breakpoint 
(/tg/ml) 
(9) 
&0. 031-8 
(I) 
0. 125 
(5) 
&0 031 0 125 
(9) 
&0. 031-1 
(13) 
&0. 031-4 
0. 0625 * 
(2) 
0. 031-0. 0625 
(6) 
&0. 031-0. 25 
(I) 
&0. 031 
(I) 
0. 0625 
(20) 
&0. 031-1 
Q 5 
(9) 
&0. 031-0. 125 
0. 125 * 
(I) 
0. 0625 
(I) 
&0. 031 
& 2 pg/mi 
(9) 
&0. 031-8 
(I) 
0. 125 
(5) 
&0 031-0 0625 
(9) 
&0. 031-0. 5 
(13) 
&0. 031-4 
&0. 031 * 
(2) 
0. 0625-0. 5 
(6) 
&0. 031-0. 25 
(I) 
&0. 031 
(I) 
0. 031 
(20) 
&0. 031-1 
0. 5 * 
(9) 
&0. 031-0. 25 
0. 125 * 
(I) 
0. 0625 
(I) 
&0. 031 
& 2 ltg/ml 
(9) 
&0. 031-&16 
(I) 
0. 25 
(5) 
&0. 031-0. 5 
(9) 
&0. 031-0. 5 
(13) 
&0. 031-&16 
0. 25 * 
(2) 
0, 125-2 
(6) 
&0. 031-0. 5 
(I) 
0. 031 
(I) 
0. 25 
(20) 
&0. 031-4 
2* 
(9) 
&0. 031-2 
0. 25 * 
(I) 
&0. 031 
(I) 
&0, 031 
& 2 Itg/ml 
(9) 
&0. 031-&16 
(I) 
0. 25 
(5) 
&0. 031-2 
(9) 
&0. 031-2 
(13) 
&0. 031-&16 
0. 125 4 
(2) 
0. 5-1 
(6) 
&Q. Q31-1 
(I) 
0. 125 
(1) 
0. 125 
(20) 
&0. 031-4 
0. 5 * 
(9) 
&0 031 05 
Q 5 
(I) 
&0. 031 
(I) 
&0. 031 
& 4 ltg/ml 
MICgp values are indicated with a *. 
isolates for each organism. 
The number in parenthesis indicates the number of 
Table 4: Patterns of resistance in bacteria against the fluorinated quinolones 
3. 17 % 
Orbifloxacin 
Difloxacin 
317% 
6. 34% 
81 ~ 2 304 
DISCUSSION 
Our results showed data did not differ among the drugs, as was expected. The 
MIC determinations of ciprofloxacin and enrofloxacin showed no significant differences. 
Therefore, we can conclude, similarly to our hypothesis, that because enrofloxacin and 
ciprofloxacin are very similar in structure, they are also similar in susceptibility patterns. 
Since both drugs showed the same susceptibility patterns, we can conclude that 
enrofloxacin can and should be used by veterinarians. Because enrofloxacin is safer for 
small animals, our studies indicate that enrofloxacin remains the better choice for 
bacterial infections in veterinary cases. As seen in Table 4, our percent of resistant 
organisms show that susceptibility patterns among the organisms studied did not vary 
from ciprofloxacin and enrofloxacin. Susceptibility, however, generally decreased for 
orbifloxacin and difloxacin compared to ciprofloxacin and enrofloxacin. This suggests 
that based on this in vitro data, enrofloxacin remains the best of the three veterinary 
fluorinated quinolones. 
The range of MIC's and some MIC9Q's of each antibiotic was developed for 
comparative purposes and is shown in Table 6. Comparing these two important 
characteristics is a thorough way of organizing and comparing efficacy among bacterial 
populations. Although only relevant to clinical cases if the organism is generally always 
resistant, our data shows that no organism is more resistant than the other. Our procedure 
using a microtiter plate proved to be very effective in determining MIC. The plate was 
clear in showing visible growth and minimum concentrations such as the plate in Figure 
20 
Because our results show that an insignificant number of bacteria have different 
MIC's for ciprofloxacin and enrofloxacin, we can conclude that both drugs have the same 
susceptibility patterns. The numbers for MIC and the resistant patterns for the bacteria 
were consistent throughout for both drugs as shown in Table 1. Both orbifloxacin and 
difloxacin exhibited similar patterns of susceptibility and MIC's. However, MIC's for 
boih of these drugs seemed to be higher than MIC's for ciprofloxacin and enrofloxacin. 
A greater number of organisms categorized as susceptible to ciprofloxacin and 
enrofloxacin were resistant to orbifloxacin and difloxacin. This led us to conclude that 
ciprofloxacin and enrofloxacin do not differ in bacterial susceptibility patterns and that 
orbifloxacin and difloxacin are less effective than ciprofloxacin and enrofloxacin. Thus, 
enrofloxacin, based on our in vitro data, is the best choice for veterinary use, 
ACKNOWLEDGEMENTS 
I would like to take a moment to give credit to where it belongs. First and 
foremost, I would like to thank and honor the Clinical Pharmacology lab for having me 
work in the laboratory for the past two and a half years. I would like to especially thank 
Dr. Boothe for always encouraging me and giving me support. And for always putting 
up with my character flaws, procrastination being one of them. She has greatly 
influenced me in the past years I have conducted research at the Clinical Pharmacology 
Lab and has always been there for me through personal problems and research hurdles. I 
greatly thank her for all she has done for me and will always honor the advice she has 
given me. Next, I could not have even gotten through the past two years without the help 
and encouragement of Dr. Albert Boeckh. He has been a great motivating force in my 
life and my career at the Clinical Pharmacology Lab. He has done more for me than I 
can even imagine and has always lend a helping hand. Thanks Albert! Finally, I would 
like to thank the Clinical Microbiology Lab, specifically Dr. Bruce Simpson, Kim 
Andrews and Rashel Mikulec. They have helped me from day one when I first picked up 
a blood agar plate and made smiley faces with my organism. Although I still am not 
perfect, they have patiently seen me through many ordeals and nouble I have encountered 
on this project. And all three have been really great friends as well. They have always 
been nice to me and tolerated listening to my problems. Thank you. More 
acknowledgements are in order to Antech Diagnostics and Antech East Diagnostics, Inc. 
Also, great appreciation is given to the Texas Veterinary Medical Diagnostic Laboratory 
(TVMDL). 
22 
REFERENCES 
Acar, J. F. and F. W. Goldstein. "Trends in Bacterial Resistance to Fluoroquinolones. " 
Clinica! Infectious Diseases, Vol 24, 1997. Pp S67-73. 
Bany, Arthur L. and Clyde Thornsberry. "Susceptibility Tests: Diffusion Test 
Procedures. " Antimicrobial Agents and Susceptibility Tests. Pp. 1117-1125. 
Boothe, Dawn M. "Principles of Antimicrobial Therapy. " Lecture Notes, Spring 1998. 
Ford, Richard, ed. Second International Veterinary Symposium on Fluoroquinolones 
Proceedings. Veterinary Learning Systems, 1996. Pp. 9-43. 
Lorian, Victor, ed. Antibiotics in Laboratory Medicine. 3" ed. Williams and Wilkins, 
Baltimore, MD, 1991, Pp. 665-690. 
Martinez-Martinez, Luis, Alvaro Pasual, and George A Jacoby. "Quinolone Resistance 
from a transferable plasmid. " The Lanclet. Vol 351, March 14, 1998. Pp. 797- 
799. 
Schaechter, Moselio, Gerald Medoff, and Barry I. Eisenstein. Mechanisms of Microbial 
Diseases. 2" ed, William and Wilkins, Baltimore, MD, 1993. Pp 40-45. 
Truong, Q. C. , Jean-Claude Nguyen Van, David Shlaes, Laurent Gutmann, and Nicole J. 
Moreau. "A Novel, Double Mutation in DNA Gyrase A of Escherichia coli 
Conferring Resistance to Quinolone Antibodies. " Antimicrobial Agents and 
Chemotherapy, Jan, 1997. pp 85-90. 
Waters, Barbara and Julian Davies. "Amino Acids Variation in the GyrA Subunit of 
Bacteria Potentially Associated with Natural Resistance to Fluoroquinolone 
Antibodies. " Antimicrobial Agents and Chemotherapy, Dec, 1997. Pp 2766- 
2769. 
Zhao, Xilin. , Chen Xu, John Domagala, and Karl Drlica. "DNA topoisomerase targets of 
the fluoroquinolones: A strategy for avoiding bacterial resistance. " Proc. 
National Academy of Science. Vol. 94, Dec. 1997. Pp 13991-13996. 
23 
